Every 10-Q that MAIA Biotechnology Inc. (MAIA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MAIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAIA filings page.
MAIA Biotechnology, Inc., a clinical-stage oncology company focused on telomere-targeting immunotherapy candidate ateganosine (THIO) for non-small cell lung cancer, reported higher operating spending and net losses for the three and six months ended June 30, 2026. For the six‑month period, research and development expenses were $9.16 million and general and administrative expenses were $6.10 million, driving a net loss of $14.31 million compared with $9.86 million a year earlier.
Cash strengthened significantly following March 2026 equity offerings, with cash of $27.60 million and working capital of $21.98 million at June 30, 2026, versus cash of $8.66 million at year‑end 2025. Net cash used in operating activities was $12.06 million for the six months, partially offset by $30.99 million of net cash from financing, mainly a confidentially marketed public offering. Total assets were $28.24 million and warrant liabilities measured at fair value were $1.31 million.
MAIA Biotechnology reported a larger net loss as it accelerated cancer drug development but significantly strengthened its balance sheet. For the three months ended March 31, 2026, net loss was $6.4 million versus $4.5 million a year earlier, driven by higher research and development and general and administrative costs.
Research and development expenses rose to $3.5 million, while general and administrative expenses increased to $3.4 million, reflecting expanded clinical activity and corporate infrastructure. Other income of $0.6 million included NIH grant income and a gain from remeasuring warrant liabilities.
Cash increased to $34.4 million from $8.7 million at year-end 2025, and working capital reached $29.0 million, mainly due to a March 2026 confidentially marketed public offering and follow-on that raised approximately $33 million gross. Management states these proceeds are expected to fully fund the pivotal Phase 3 trial of lead asset ateganosine (THIO) in non-small cell lung cancer.
Clinically, MAIA reported overall survival beyond two years for eight NSCLC patients in its Phase 2 THIO-101 trial, activated the first U.S. site in the study’s expansion, and continues planning Phase 2 programs in hepatocellular, colorectal, and small cell lung cancers.
MAIA Biotechnology reported a wider quarterly loss and flagged liquidity risk in its Q3 results. For the quarter ended September 30, 2025, the company posted a net loss of $8.9 million as operating expenses rose, driven by research and development.
Cash was $10.9 million with working capital of approximately $1.76 million. Management stated there is substantial doubt about the company’s ability to continue as a going concern within one year without additional financing. Operating cash outflow was $11.8 million for the nine months, partially offset by financing inflows of $13.1 million, including at-the-market share sales and multiple private placements.
Quarterly operating expenses were $9.36 million (R&D $6.36 million; G&A $3.00 million). The warrant liability decreased to $1.75 million, contributing to other income. Shares outstanding were 34.45 million at quarter-end; authorized common shares were increased to 150 million earlier in the year. As of November 7, 2025, common shares outstanding were 37,032,307.
MAIA Biotechnology, Inc. reported unaudited condensed consolidated results for the quarter ended June 30, 2025. The company held $10,144,522 in cash and reported total assets of $11,045,854 and total liabilities of $7,169,170, leaving stockholders' equity of $3,876,684. The company had 31,818,480 shares issued and outstanding at June 30, 2025 and 32,993,220 shares outstanding as of August 11, 2025.
Operating expenses for the quarter were $5.17 million (R&D $3.11M; G&A $2.06M). Net loss was $5.35 million in the quarter and $9.86 million for the six months, narrower than the prior-year six-month loss of $16.95M; basic and diluted loss per share was $0.34 for the six months. Net cash used in operating activities for six months was $8.34 million; net cash provided by financing activities was $8.87 million from ATM sales and multiple private placements.
The filing discloses substantial doubt about the company’s ability to continue as a going concern within one year, noting an accumulated deficit of $97,099,055 and that additional equity or debt financing will be required.